In a 1:1 matched retrospective cohort of 300 adults with ulcerative colitis (UC), GLP-1 receptor agonist use (liraglutide or semaglutide) for metabolic indications was independently associated with a 5.90-fold adjusted odds of symptomatic remission at 12 weeks (95% CI 3.52–9.86) versus matched controls. Remission rates diverged sharply — 66.7% vs. 25.3% by week 12 — and mean partial Mayo scores dropped from 5.8 to 2.1 in the GLP-1 RA group. Weight loss did not mediate the effect, and semaglutide outperformed liraglutide (72.5% vs. 60%; OR 1.77). A subset showed higher endoscopic remission rates as well (58% vs. 38%).
The magnitude of these associations is striking and mechanistically plausible. GLP-1 receptors are expressed on intestinal epithelial cells, lamina propria immune cells, and enteric neurons. Preclinical data have shown GLP-1 signaling suppresses NF-κB–driven mucosal inflammation and promotes epithelial barrier integrity — pathways directly relevant to UC pathophysiology. The dissociation from weight loss here is a critical finding, pointing toward a direct immunomodulatory mechanism rather than metabolic secondary effects.
That said, the study's retrospective single-center design, modest cohort size, and potential for residual confounding — particularly around baseline immunosuppressive therapies — limit causal inference. Selection bias is a real concern: patients stable enough to receive GLP-1 RAs for metabolic indications may already have less refractory disease. This is hypothesis-generating and arguably the most compelling observational signal for GLP-1 RAs in IBD to date, warranting urgent prospective randomized trials.